surmount-1 tirzepatide trial obesity without diabetes for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Tirzepatide for Obesity: Highlights from
Description
Clinicians assess prescription weight loss candidacy by reviewing BMI, medical history, current medications, mental health, previous weight loss efforts, and safety risks
This suggests that tirzepatide is more effective in improving glucose control in patients with T2DM [87, 88]
7 In addition, tirzepatide will reduce body weight by an average of 7.6 to 11.2 kg (16.8 to 24.7 lb) depending on the dose
Confirm current details directly on the official website before enrolling
Retrieved from Wadden, T
In the placebo group, only 0.7% reported it
